Shankar Gopi

Chief Development Officer

Shankar Gopi has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Nov 12, 2026.

On the most recent filing, Shankar Gopi is listed as Chief Development Officer at Larimar Therapeutics, Inc. Inside the rolling window, Shankar Gopi reported 1 open-market purchase totaling $14K in LRMR and no open-market sales.

Companies traded

Other insiders at LRMR

Insider Buying

$14K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
LRMRPurchase$14KNov 12SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Shankar Gopi made?

Shankar Gopi has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.

Which companies does Shankar Gopi trade?

Shankar Gopi has filed SEC Form 4 disclosures for 1 company, including LRMR.

When was Shankar Gopi's most recent SEC Form 4 filing?

Shankar Gopi's most recent SEC Form 4 filing on Tracefour is dated Nov 12, 2026.

What is Shankar Gopi's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Shankar Gopi is listed as Chief Development Officer.

What is Shankar Gopi's total buy and sell value in the current window?

Inside the rolling retention window, Shankar Gopi bought $14K and sold $0 based on SEC Form 4 filings.

What was Shankar Gopi's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 5,000 LRMR shares on 2026-11-11, worth $14K, per SEC Form 4 filings.